NASDAQ$ZYXIQ

Zynex Inc · Q4 2022 earnings

Q4 2022 earnings · · Investor relations

Briefing

Reported a 21% increase in net revenue and a 53% increase in net income compared to Q3 2022.

Zynex, Inc. reported strong Q4 2022 financial results with a 21% increase in net revenue and a 53% increase in net income from the previous quarter. The company's cash flow from operations allowed for significant stock buybacks, and Zynex Monitoring Solutions is making progress with clinical data collection.

  • Net revenue increased by 21% compared to Q4 2021.
  • Net income increased by 53% compared to Q3 2022.
  • Cash on hand was $20.1 million at the end of the fourth quarter.
  • The company bought back over $26 million of its common stock during 2022.

Headline financials

Total Revenue

$48.8M

Previous: $40.4M+20.9%
EPS (adj)

$0.20

Previous: $0.23-13.0%
Capital Expenditures

$86K

Previous: $189K-54.5%
Free Cash Flow

$4.67M

Previous: $7.35M-36.4%
Net Income

$7.5M

Previous: $8.9M-15.7%
Operating Income

$10.1M

Previous: $11.6M-12.7%
Gross Profit

$39.4M

Previous: $33.1M+19.0%
Cash & Equivalents

$20.1M

Previous: $42.6M-52.8%
Total Assets

$116M

Previous: $133M-12.6%
Stock-Based Comp

$640K

Previous: $588K+8.8%

Revenue & EPS history

Zynex · Revenue · Quarterly

$48.8M

Q4 2022+20.9%vs Q4 2021
Beat estimate in 7 of 16 quarters(44%)
ActualEstimate

Revenue by segment

Zynex · $49.9M total across 2 segments · Q3 2023

  • Supplies
    $33.1M
  • Devices
    $16.9M

Forward guidance

Full year 2023 revenue is estimated to range between $180 - $200 million and with Diluted EPS of $0.40 - $0.50 per share. First quarter 2023 revenue is estimated to range between $39.0 - $41.0 million, an increase of approximately 29% from Q1 2022. First quarter Diluted EPS is estimated to range between $0.00- $0.03.

Tailwinds

  • Full year 2023 revenue is estimated to range between $180 - $200 million.
  • Full year 2023 Diluted EPS is estimated to range between $0.40 - $0.50 per share.
  • First quarter 2023 revenue is estimated to range between $39.0 - $41.0 million.
  • First quarter 2023 revenue represents an increase of approximately 29% from Q1 2022.

Headwinds

  • Diluted EPS is impacted by increased operating expenses to support ZMS.
  • Increased operating expenses are to support ZMS as the Laser-based Pulse Oximetry products are prepared for FDA submission and the fluid monitor is readied for the market.
  • First quarter revenue is affected by the resetting of health insurance deductibles in the beginning of a calendar year.
  • Seasonably lower revenues in the first quarter are a historical trend for Zynex and an industry norm.
  • First quarter Diluted EPS is estimated to range between $0.00- $0.03.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q4 2022

Historical avgQ4 2022

+0.4%

Avg return

Earnings day

-1.8%

Avg return

5 days after

-6.5%

Avg return

30 days after

46%

29 / 63 earnings

Positive

+38.5%

Q3 2014

Best reaction

-51.6%

Q1 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2024-51.3%
Q3 2025+0.0%+0.0%-98.2%
Q2 2025+0.0%+0.0%+0.0%
Q1 2025-25.6%+0.0%+0.0%
Q3 2024+9.1%+0.0%+0.0%
Q2 2024-11.4%+0.0%+0.0%
Q1 2024+2.8%+0.0%+0.0%
Q4 2023-8.8%+0.0%+0.0%
Q3 2023+17.5%+0.0%+0.0%
Q2 2023+3.3%+0.0%+0.0%
Q1 2023+2.5%+0.0%+0.0%
Q4 2022+16.7%+0.0%+0.0%
Q3 2022+15.0%+0.0%+0.0%
Q2 2022+13.3%+0.0%+0.0%
Q1 2022-8.6%+0.0%+0.0%
Q4 2021-1.7%+0.0%+0.0%
Q3 2021+10.0%+0.0%+0.0%
Q2 2021-19.3%+0.0%+0.0%
Q1 2021-9.2%-12.0%-6.3%
Q4 2020-21.2%-22.4%-18.8%
Q3 2020-6.5%
Q2 2020-6.0%
Q1 2020-1.1%
Q4 2019+3.1%
Q3 2019-7.9%
Q2 2019+9.8%
Q1 2019+7.9%
Q4 2018-11.1%
Q3 2018+3.4%
Q2 2018-3.3%
Q1 2018+4.5%
Q4 2017-20.7%
Q3 2017+6.6%
Q2 2017+34.6%
Q1 2017-5.6%
Q4 2016+9.7%
Q3 2016+23.1%
Q2 2016+34.8%
Q1 2016+0.0%
Q4 2015+0.0%
Q3 2015-4.3%
Q2 2015-5.4%
Q4 2014+0.0%
Q1 2015+0.0%
Q3 2014+38.5%
Q2 2014+2.2%
Q1 2014-0.2%
Q4 2013-3.6%
Q3 2013+13.6%
Q2 2013+7.1%
Q1 2013+0.0%
Q4 2012+3.4%
Q3 2012+5.6%
Q2 2012-5.1%
Q1 2012-6.3%
Q4 2011+0.0%
Q3 2010+12.9%
Q3 2011+12.9%
Q2 2011+1.1%
Q1 2011-8.2%
Q4 2010+0.0%
Q2 2010+2.0%
Q1 2010-51.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro